Omeros Corp
OMER
查看详细走势图
15.900USD
+7.150+81.71%
交易中 （美东）报价延迟15分钟
1.11B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+81.71%
5天
+81.40%
1月
+79.25%
6月
+398.43%
今年开始到现在
+60.93%
1年
+57.27%
查看详细走势图
TradingKey Omeros Corp股票评分
单位: USD 更新时间: 2025-12-23操作建议
Omeros Corp当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名175/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价33.67。中期看，股价处于上升通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Omeros Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
5
位分析师
买入
评级
33.667
目标均价
+195.32%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Omeros Corp亮点
亮点风险
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Omeros Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Omeros Corp简介
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
公司代码OMER
公司Omeros Corp
CEODemopulos (Gregory A)
网址https://www.omeros.com/
常见问题
Omeros Corp(OMER)的当前股价是多少？
Omeros Corp(OMER)的当前股价是 15.900。
Omeros Corp的股票代码是什么？
Omeros Corp的股票代码是OMER。
Omeros Corp股票的52周最高点是多少？
Omeros Corp股票的52周最高点是12.100。
Omeros Corp股票的52周最低点是多少？
Omeros Corp股票的52周最低点是2.950。
Omeros Corp的市值是多少？
Omeros Corp的市值是1.11B。
Omeros Corp的净利润是多少？
Omeros Corp的净利润为-156.81M。
现在Omeros Corp(OMER)的股票是买入、持有还是卖出？
根据分析师评级，Omeros Corp(OMER)的总体评级为买入，目标价格为33.667。
Omeros Corp(OMER)股票的每股收益（EPS TTM）是多少
Omeros Corp(OMER)股票的每股收益（EPS TTM）是-2.012。
相关品种
